Get the Stockscreener App
32.03
0.59%
-0.19
After Hours:
32.03
Overview
News
Price History
Option Chain
Financials
Why TEVA Down?
Discussions
Forecast
Stock Split
Dividend History
Teva Pharmaceutical Industries Ltd Adr stock is traded at $32.03, with a volume of 3.61M.
It is down -0.59% in the last 24 hours and down -1.63% over the past month.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
See More
Previous Close:
$32.22
Open:
$32.13
24h Volume:
3.61M
Relative Volume:
0.59
Market Cap:
$37.30B
Revenue:
$17.53B
Net Income/Loss:
$1.58B
P/E Ratio:
23.80
EPS:
1.3457
Net Cash Flow:
$444.18M
1W Performance:
-2.79%
1M Performance:
-1.63%
6M Performance:
+0.85%
1Y Performance:
+96.38%
1-Day Range:
$31.95
$32.69
1-Week Range:
$31.28
$32.81
52-Week Range:
$14.99
$37.34
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Name
Teva Pharmaceutical Industries Ltd Adr
Sector
Phone
972 (3) 914-8213
Address
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.03 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
TAK
Takeda Pharmaceutical Co Adr
|
17.15 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.10 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
76.56 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
535.67 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Dec-05-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-06-25 | Initiated | Goldman | Buy |
| May-28-25 | Initiated | Truist | Buy |
| May-12-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-10-24 | Upgrade | Argus | Hold → Buy |
| Mar-08-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-12-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-23-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Upgrade | Piper Sandler | Underweight → Neutral |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Nov-27-23 | Upgrade | UBS | Neutral → Buy |
| Jul-06-23 | Upgrade | UBS | Sell → Neutral |
| May-25-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-19-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-14-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | UBS | Neutral → Sell |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Aug-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-14-22 | Resumed | UBS | Neutral |
| May-17-22 | Upgrade | BofA Securities | Underperform → Neutral |
| May-04-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Apr-05-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-25-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-27-22 | Downgrade | Argus | Buy → Hold |
| Oct-28-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-04-21 | Downgrade | UBS | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-25-20 | Initiated | Oppenheimer | Perform |
| Aug-06-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-27-20 | Resumed | Goldman | Neutral |
| Jun-01-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-24-20 | Resumed | Citigroup | Neutral |
| Apr-06-20 | Upgrade | UBS | Neutral → Buy |
| Feb-24-20 | Downgrade | Edward Jones | Hold → Sell |
| Nov-12-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-07-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-19-19 | Initiated | Wolfe Research | Peer Perform |
| Jul-15-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Jul-05-19 | Upgrade | Argus | Hold → Buy |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Jun-03-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| May-28-19 | Downgrade | UBS | Buy → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Mar-07-19 | Resumed | UBS | Buy |
View All
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News
What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders - Sahm
MINT,TEVA Volatility & Greeks - Finviz
Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap? - Sahm
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
Teva (TEVA) Stock Looks Reasonable Even With A 48% Gap - Sahm
Teva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progress - Sahm
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? - The Motley Fool
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis - Sahm
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial - Sahm
TEVA Stock Price | Analyst Target 42.38 & Strong Buy Consensus - eToro
Teva stock leans on its generic drug base. - ad-hoc-news.de
883035 Forecast — Price Target — Prediction for 2027 - TradingView
TEVATeva- Pharmaceutical Industries Ltd ADR Latest SEC Filings - Finviz
How Teva’s Ecopipam NDA for Pediatric Tourette Syndrome (TEVA) Has Changed Its Investment Story - Sahm
TEVA Stock Price, Quote & Chart - ChartMill
Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView
Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – BX:TEV - TradingView
TEV Forecast — Price Target — Prediction for 2027 - TradingView
TEVA Forecast — Price Target — Prediction for 2027 - TradingView
TEVA/N Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Price to earnings forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Enterprise value to EBITDA forward of Teva Pharmaceutical Industries Limited Sponsored ADR – FWB:TEV - TradingView
Teva Pharmaceutical Industries Ltd Unsponsored Brazilian Depositary Receipt Repr 0.5 ADR - TradingView
Teva Pharmaceutical Industries Limited Sponsored ADR - TradingView
TEVA News | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill
Teva's Shift Beyond Generics Puts Focus on Branded Drug Growth - TradingView
How Teva’s Ecopipam Tourette NDA and AUSTEDO Data Will Impact Teva Pharmaceutical Industries (TEVA) Investors - Sahm
Teva Pharmaceutical Industries (TEVA) Stock Could Be 23.7% Undervalued After Recent Pullback - Sahm
Teva Seeks FDA Nod for Ecopipam in Pediatric Tourette Syndrome - Yahoo Finance
Teva submits new drug application for pediatric Tourette treatment By Investing.com - Investing.com Canada
FOCUS-US progesterone supplies tighten as menopause treatment demand grows - Sahm
Teva Extends Neuroscience Focus With Emalex Deal And Valuation Upside Potential - Sahm
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy - Sahm
symbol__ Stock Quote Price and Forecast - CNN
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs - TradingView
How Investors May Respond To Teva (TEVA) Pivoting From Generics Toward Higher-Margin Branded Therapies - Sahm
Teva stock hits 52-week high at $32.02 By Investing.com - Investing.com Nigeria
Assessing Teva (NYSE:TEVA) Valuation After New IMPACT-TD Registry Findings On Tardive Dyskinesia - Sahm
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Flags Technical Breakout Setup with Top Ratings - ChartMill
Teva- Pharmaceutical Industries Ltd.ADR (TEVA) News, Articles, Events & Latest Updates - Stocktwits
Updating Moat and Valuation for Teva to Reflect Improved Outlook - Morningstar
Teva: Upgrading Moat and Raising Valuation on Portfolio Improvements and Deep Pipeline - Morningstar
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today - Sahm
A Look At Teva (NYSE:TEVA) Valuation After EMA Accepts Filing For Monthly Schizophrenia Injection - Sahm
Teva Pharmaceutical Industries Limited Sponsored ADR Trade Ideas — LSX:883035 - TradingView
Will Teva’s New TD Data on Young Adults Shift Its Neuroscience-Focused Investment Narrative (TEVA)? - Sahm
Teva Pharmaceutical’s SWOT analysis: stock navigates growth reset - Investing.com
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):